Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications

Journal of Cosmetic and Laser Therapy

Volumn 10, Issue 3, 2008, Pages 181-183

  Pickett, Andy ^a   Dodd, Stephen ^b   Rzany, Berthold ^c  

^a IPSEN   (France)

^b UNIVERSITY OF FLORIDA   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

CEREBRAL PALSY; CYTOPLASM; DATA ANALYSIS; DISSOCIATION; DRUG DISTRIBUTION; DRUG POTENCY; DRUG PURIFICATION; ESTHETICS; FOREHEAD; HUMAN; HYPERHIDROSIS; LETTER; MOLECULAR SIZE; NONHUMAN; PRIORITY JOURNAL; PTOSIS; TREATMENT INDICATION;

BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; COSMETIC TECHNIQUES; HUMANS;

EID: 51649105769     PISSN: 14764172     EISSN: 14764180     Source Type: Journal    
DOI: 10.1080/14764170802094282     Document Type: Letter

References (27)

1. De Almeida AT, de Boulle K. Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther. 2007;9(suppl 1):17-22.
2. Aoki R, Francis J, Reynolds H, Leumer D. Comparison of the therapeutic windows of different neurotoxin preparations in an animal model. Neurol. 2003;60(5, suppl 1):A212-13.
3. Francis J, Satorius AL, Ardila MC, Brown MS, Nicholson GS, Aoki KR. Pharmacological evaluation of BOTOX®, Dysport® and Myobloc® in pre-clinical models of efficacy and safety. Presented at the 10th Congress of the European Federation of Neurological Societies (EFNS 2006). September 2006; poster P1169.
4. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006;13(suppl 4):10-19.
5. BOTOX® summary of product characteristics. Allergan Ltd, UK; 7 June 2007.
6. Pickett AM, Hambleton P. Dose standardisation of botulinum toxin. Lancet. 1994;344:474-5.
7. Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med. 1994;87:719.
8. Pearce LB, Borodic GE, First ER, MacCallum RD. Measurement of botulinum toxin activity: Evaluation of the lethality assay. Toxicol Appl Pharmacol. 1994;128:69-77.
9. Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B and F in mice. Toxicon. 2001;39:1815-20.
10. Aoki KR, Satorius A, Ardila C, Brown M, Nicholson G, Francis J. Pharmacology of BOTOX®, Dysport® and Myobloc® and BoNT/A in animal models of safety and efficacy. Neurotox Res. 2006;9:236.
11. Pickett A, O'Keeffe R, Panjwani N. The protein load of therapeutic botulinum toxins. Eur J Neurol. 2007;14:e11.
12. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: Differences between Type A preparations. Eur J Neurol. 2006;13(suppl 1):2-10.
13. BOTOX® prescribing information. Allergan Inc, USA; October 2006.
14. De Almeida ART, Marques E, de Almeida J, Cunha T, Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin Type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007;33:S37-43.
15. Bihari K. Safety, effectiveness, and duration of effect of BOTOX® compared with Dysport® for blepharospasm, cervical dystonia, and hemifacial spasm. Presented at the 7th Congress of the European Federation of Neurological Societies. Helsinki, Finland; August 30 - September 2, 2003.
16. Karsai S, Adrian R, Hammes S, Thimm J, Raulin C. A randomized double-blind study of the effect of botox and dysport/reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol. 2007;143:1447-9.
17. Hexsel D, Dal'Forno T, Hexsel C, do Prado DZ. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin Type A. Dermatol Surg. 2007;34:1-8.
18. Hexsel D, Dal T, do Prado DZ, Hexsel C. Diffusion, dispersion, or action halos of botulinum toxins? A pilot study comparing two commercial preparations of Type A botulinum toxins. J Am Acad Dermatol. 2005;52(3, suppl 2):AB2.
19. Friday D, Bigalke H, Frevert J. In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. Naunyn Schmiedebergs Arch Pharmacol. 2002;365(suppl 2):R20.
20. Frevert J, Rummel A, Bigalke H. Stability of BoNT/A complex at physiological conditions. Presented at the 44th Meeting of the Interagency Botulism Coordinating Committee. California, 2007; Poster SF-4.
21. Wagman J, Bateman JB. Botulinum Type A toxin: Properties of a toxic dissociation product. Arch Biochem Biophys. 1953;45:375-83.
22. Dodd SL, Rowell BA, Vrabas IS, Arrowsmith RJ, Weatherill PJ. A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function. Eur J Neurol. 1998;5:181-6.
23. Tang-Liu DD-S, Aoki KR, Dolly JO, de Paiva A, Houchen TL, Chasseaud LF, et al. Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: Time course of tissue distribution. Toxicon. 2004;42:461-9.
24. Lowe P, Patnaik R, Lowe NJ. A comparison of two botulinum Type A toxin preparations for the treatment of glabellar lines: Double-blind, randomized, pilot study. Dermatol Surg. 2005;31:1651-4.
25. Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin Type A for the treatment of glabellar lines: A double-blind, randomized study. J Am Acad Dermatol. 2006;55:976-82.
26. Rzany B, Nast A. Head-to-head studies of botulinum toxin A in aesthetic medicine: Which evidence is good enough? (Letter). J Am Acad Dermatol. 2007;56:1066-7.
27. De Maio M, Rzany B. Botulinum toxin in aesthetic medicine. Heidelberg: Springer; 2007.